New hope for myeloma patients out of options: experimental drug enters human testing
Disease control
Not yet recruiting
This is a first-in-human study to test a new drug called IBI3003 for adults with multiple myeloma that has returned or stopped responding to at least three prior treatments. The first part aims to find a safe and tolerable dose. The second part will explore if the drug can help c…
Phase: PHASE1, PHASE2 • Sponsor: Fortvita Biologics (USA)Inc. • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC